Amneal Reports Third Quarter 2024 Financial Results

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Negative)

Insights

The Q3 results show mixed performance with notable revenue growth but compressed margins. Total revenue reached $702 million, up 13% year-over-year, driven by strong performance across all segments. Generics grew 9%, Specialty increased 19% and AvKARE rose 21%.

However, profitability metrics were less impressive. The company posted a small net loss of $0.2 million compared to $10 million profit last year, primarily due to higher interest expenses. Adjusted EBITDA grew modestly by 2% to $158 million, impacted by a $20 million R&D milestone payment. Adjusted EPS declined to $0.16 from $0.19.

The company maintained its full-year guidance, projecting revenue of $2.70-2.80 billion and adjusted EBITDA of $610-630 million, suggesting confidence in its growth trajectory despite margin pressures.

The strategic developments in Amneal's portfolio are significant. The launch of CREXONT® for Parkinson's disease expands their neurology franchise. The collaboration with Metsera for obesity and metabolic medicines positions them in a rapidly growing therapeutic area. The in-licensing of a new biosimilar strengthens their biosimilars pipeline, which has been a growth driver.

The $20 million R&D milestone payment for Omalizumab demonstrates commitment to pipeline expansion in high-value biologics. The company's diversification strategy across generics, specialty products and biosimilars provides multiple growth avenues while reducing dependency on any single product line.

11/08/2024 - 06:00 AM

‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒

‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒

‒ Affirms 2024 Full Year Guidance ‒

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2024.

“Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth. First, we launched CREXONT® for the treatment of Parkinson’s disease. Second, we announced our collaboration with Metsera, Inc. to leverage Amneal’s expertise and supply next-generation medicines for obesity and metabolic diseases. Third, we expanded our deep pipeline by in-licensing a new high-value biosimilar. We look forward to building on our momentum and continuing to create value for all our key stakeholders,” said Chirag and Chintu Patel, Co-Chief Executive Officers.

Third Quarter 2024 Results

Net revenue in the third quarter of 2024 was $702 million, an increase of 13% compared to $620 million in the third quarter of 2023. Generics net revenue increased 9% driven by strong performance of new product launches and biosimilars. Specialty net revenue increased 19% driven by promoted products in neurology and endocrinology, including the recent launches of CREXONT^® and ONGENTYS^® for Parkinson’s disease. AvKARE net revenue increased 21% driven by growth across its distribution and government label sales channels.

Net loss attributable to Amneal Pharmaceuticals, Inc. was $0.2 million in the third quarter of 2024 compared to net income of $10 million in the third quarter of 2023, primarily due to higher interest expense.

Adjusted EBITDA in the third quarter of 2024 was $158 million, an increase of 2% compared to the third quarter of 2023, reflective of strong revenue performance and higher gross margins, partially offset by a $20 million research and development milestone payment associated with the Company’s exclusive license of Omalizumab during the third quarter of 2024.

Diluted loss per share in the third quarter of 2024 was $0.00 compared to diluted income per share of $0.06 for the third quarter of 2023, as higher interest expense reduced net income. Adjusted diluted earnings per share in the third quarter of 2024 was $0.16 compared to $0.19 for the third quarter of 2023 due to the aforementioned factor.

The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please refer to the “Non-GAAP Financial Measures” section for more information. In the tables provided below, GAAP to non-GAAP reconciliations are presented.

Affirming Previously Announced Increased 2024 Full Year Guidance

Net revenue	$2.70 billion - $2.80 billion
Adjusted EBITDA ⁽¹⁾	$610 million - $630 million
Adjusted diluted EPS ⁽²⁾	$0.57 - $0.63
Operating cash flow ⁽³⁾	$280 million - $320 million
Capital expenditures	$60 million - $70 million

⁽¹⁾		Includes 100% of Adjusted EBITDA from the AvKARE acquisition.
⁽²⁾		Accounts for 35% non-controlling interest in AvKARE. Guidance assumes approximately 320 million weighted-average diluted shares outstanding for the year ending December 31, 2024.
⁽³⁾		Does not contemplate one-time and non-recurring items such as legal settlements and other discrete items.

Amneal’s 2024 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

Conference Call Information

Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, November 8, 2024, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial (833) 470-1428 (in the U.S.) with access code 088741. A replay of the conference call will be posted shortly after the call and will be available for seven days. For a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=68226.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 generic and specialty pharmaceuticals, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the impact of a prolonged business interruption within our supply chain; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted EPS, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP. Adjusted diluted EPS reflects diluted earnings per share based on adjusted net income (loss), which is net income (loss) adjusted to (A) exclude (i) non-cash interest, (ii) GAAP provision for (benefit from) income taxes, (iii) amortization, (iv) stock-based compensation expense, (v) acquisition, site closure expenses, and idle facility expenses, (vi) restructuring and other charges, (vii) (credit) charges related to certain legal matters, including interest, net, (viii) asset impairment charges, (ix) change in fair value of contingent consideration, (x) increase in tax receivable agreement liability, (xi) system implementation expense, (xii) other and (xiii) net income attributable to non-controlling interests not associated with our Class B common stock, and (B) include non-GAAP provision for income taxes. Non-GAAP adjusted diluted EPS for the three and nine months ended September 30, 2024 was calculated using the weighted average fully diluted shares outstanding of Class A common stock. Non-GAAP adjusted diluted EPS for the three and nine months ended September 30, 2023 was calculated using the weighted average diluted shares outstanding of Class A common stock and assuming all shares of Class B common stock were converted to shares of Class A common stock as of January 1, 2023.

Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations and trends while viewing the information through the eyes of management.

These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.

A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.


Amneal Pharmaceuticals, Inc.
Consolidated Statements of Operations
(unaudited; $ in thousands, except per share amounts)

	Three Months Ended September 30,				Nine Months Ended September 30,
		2024		2023		2024		2023
Net revenue	$	702,468	$	620,040	$	2,063,439	$	1,776,626
Cost of goods sold		432,910		387,509		1,305,874		1,145,888
Gross profit		269,558		232,531		757,565		630,738
Selling, general and administrative		118,692		113,006		347,749		320,672
Research and development		61,097		41,375		136,449		117,864
Intellectual property legal development expenses		1,967		886		3,993		3,350
Restructuring and other charges		172		1,043		1,862		1,635
Change in fair value of contingent consideration		(1,030)		3,120		(930)		(787)
(Credit) charges related to legal matters, net		(149)		(2,620)		94,909		(1,039)
Other operating expense (income)		—		73		—		(1,138)
Operating income		88,809		75,648		173,533		190,181
Other (expense) income:
Interest expense, net		(65,511)		(50,909)		(196,933)		(151,081)
Foreign exchange gain (loss), net		2,274		(2,939)		815		(617)
Increase in tax receivable agreement liability		(11,327)		(677)		(26,719)		(1,908)
Other income, net		1,178		1,834		9,610		6,616
Total other expense, net		(73,386)		(52,691)		(213,227)		(146,990)
Income (loss) before income taxes		15,423		22,957		(39,694)		43,191
Provision for (benefit from) income taxes		3,666		(2,076)		13,440		(1,431)
Net income (loss)		11,757		25,033		(53,134)		44,622
Less: Net income attributable to non-controlling interests		(11,913)		(15,351)		(32,671)		(29,966)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.	$	(156)	$	9,682	$	(85,805)	$	14,656

Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:
Basic	$	(—)	$	0.06	$	(0.28)	$	0.10
Diluted	$	(—)	$	0.06	$	(0.28)	$	0.09
Weighted-average common shares outstanding⁽¹⁾:
Basic		309,647		154,219		308,685		153,363
Diluted		309,647		159,691		308,685		156,284

⁽¹⁾

Following the implementation of the previously disclosed reorganization on November 7, 2023, all outstanding shares of Old PubCo Class A Common Stock and Old PubCo Class B Common Stock were exchanged for an equivalent number of shares of Class A common stock of the Company. Refer to Note 1. Nature of Operations and Note 8. (Loss) Earnings per Share to the consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K for additional information.


Amneal Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(unaudited; $ in thousands)

	September 30, 2024		December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	74,006	$	91,542
Restricted cash		4,339		7,565
Trade accounts receivable, net		748,055		613,732
Inventories		596,359		581,384
Prepaid expenses and other current assets		81,956		82,685
Related party receivables		8,579		955
Total current assets		1,513,294		1,377,863
Property, plant and equipment, net		431,020		447,574
Goodwill		598,324		598,629
Intangible assets, net		780,189		890,423
Operating lease right-of-use assets		32,872		30,329
Operating lease right-of-use assets - related party		11,473		12,954
Financing lease right-of-use assets		57,532		59,280
Other assets		36,274		55,517
Total assets	$	3,460,978	$	3,472,569
Liabilities and Stockholders' (Deficiency) Equity
Current liabilities:
Accounts payable and accrued expenses	$	671,085	$	534,662
Current portion of liabilities for legal matters		30,181		76,988
Revolving credit facility		140,000		179,000
Current portion of long-term debt, net		224,692		34,125
Current portion of operating lease liabilities		9,702		9,207
Current portion of operating lease liabilities - related party		3,327		2,825
Current portion of financing lease liabilities		3,300		2,467
Related party payables - short term		12,922		7,321
Total current liabilities		1,095,209		846,595
Long-term debt, net		2,169,607		2,386,004
Note payable - related party		—		41,447
Operating lease liabilities		26,210		24,095
Operating lease liabilities - related party		10,265		12,787
Financing lease liabilities		57,558		58,566
Related party payables - long term		26,186		11,776
Liabilities for legal matters - long term		85,479		316
Other long-term liabilities		24,144		29,679
Total long-term liabilities		2,399,449		2,564,670
Redeemable non-controlling interests		59,887		41,293
Total stockholders' (deficiency) equity		(93,567)		20,011
Total liabilities and stockholders' (deficiency) equity	$	3,460,978	$	3,472,569


Amneal Pharmaceuticals, Inc.
Consolidated Statements of Cash Flows
(unaudited; $ in thousands)

	Nine Months Ended September 30,
		2024		2023
Cash flows from operating activities:
Net (loss) income	$	(53,134)	$	44,622
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization		170,061		172,467
Unrealized foreign currency (gain) loss		(754)		1,563
Amortization of debt issuance costs and discount		2,662		6,884
Intangible asset impairment charges		920		2,036
Change in fair value of contingent consideration		(930)		(787)
Stock-based compensation		20,558		20,848
Inventory provision		63,611		56,637
Other operating charges and credits, net		(50)		6,370
Changes in assets and liabilities:
Trade accounts receivable, net		(134,031)		49,055
Inventories		(78,545)		(103,092)
Prepaid expenses, other current assets and other assets		(2,082)		24,810
Related party receivables		(483)		(1,131)
Accounts payable, accrued expenses and other liabilities		168,879		(74,685)
Related party payables		20,339		4,157
Net cash provided by operating activities		177,021		209,754
Cash flows from investing activities:
Purchases of property, plant and equipment		(36,769)		(33,351)
Acquisition of intangible assets		(14,050)		(2,488)
Deposits for future acquisition of property, plant and equipment		(1,107)		(1,658)
Proceeds from sale of subsidiary		4,989		—
Net cash used in investing activities		(46,937)		(37,497)
Cash flows from financing activities:
Payments of deferred financing and refinancing costs		—		(542)
Payments of principal on debt, revolving credit facilities, financing leases and other		(133,383)		(151,510)
Borrowings on revolving credit facilities		48,000		110,000
Proceeds from exercise of stock options		1,003		408
Employee payroll tax withholding on restricted stock unit vesting		(7,565)		(2,222)
Tax distributions to non-controlling interests		(14,442)		(67,875)
Payment of principal on notes payable - related party		(44,200)		—
Net cash used in financing activities		(150,587)		(111,741)
Effect of foreign exchange rate on cash		(259)		(136)
Net (decrease) increase in cash, cash equivalents, and restricted cash		(20,762)		60,380
Cash, cash equivalents, and restricted cash - beginning of period		99,107		35,227
Cash, cash equivalents, and restricted cash - end of period	$	78,345	$	95,607
Cash and cash equivalents - end of period	$	74,006	$	86,929
Restricted cash - end of period		4,339		8,678
Cash, cash equivalents, and restricted cash - end of period	$	78,345	$	95,607


Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited, $ in thousands)

Reconciliation of Net Income (Loss) to EBITDA and Adjusted EBITDA

	Three Months Ended September 30,				Nine Months Ended September 30,
		2024		2023		2024		2023
Net income (loss)	$	11,757	$	25,033	$	(53,134)	$	44,622
Adjusted to add:
Interest expense, net		65,511		50,909		196,933		151,081
Provision for (benefit from) income taxes		3,666		(2,076)		13,440		(1,431)
Depreciation and amortization		58,961		57,206		170,061		172,467
EBITDA (Non-GAAP)	$	139,895	$	131,072	$	327,300	$	366,739
Adjusted to add (deduct):
Stock-based compensation expense		7,112		6,691		20,343		20,848
Acquisition, site closure, and idle facility expenses ⁽¹⁾		551		1,551		1,574		5,831
Restructuring and other charges		172		1,043		1,773		1,536
(Credit) charges related to legal matters, net ⁽²⁾		(149)		2,880		94,909		8,961
Asset impairment charges		181		808		1,196		2,879
Foreign exchange (gain) loss		(2,274)		2,939		(815)		617
Change in fair value of contingent consideration		(1,030)		3,120		(930)		(787)
Increase in tax receivable agreement liability		11,327		677		26,719		1,908
System implementation expense ⁽³⁾		257		2,016		2,029		4,429
Other		1,581		1,001		(1,913)		3,105
Adjusted EBITDA (Non-GAAP)	$	157,623	$	153,798	$	472,185	$	416,066


Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited; in thousands, except per share amounts)

Reconciliation of Net Income (Loss) to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share

	Three Months Ended September 30,				Nine Months Ended September 30,
		2024		2023		2024		2023
Net income (loss)	$	11,757	$	25,033	$	(53,134)	$	44,622
Adjusted to add (deduct):
Non-cash interest		923		2,048		1,552		6,001
GAAP provision for (benefit from) income taxes		3,666		(2,076)		13,440		(1,431)
Amortization		41,992		39,091		119,481		118,011
Stock-based compensation expense		7,112		6,691		20,343		20,848
Acquisition, site closure expenses, and idle facility expenses ⁽¹⁾		551		1,551		1,574		5,831
Restructuring and other charges		172		1,043		1,756		1,536
(Credit) charges related to legal matters, including interest, net ⁽²⁾		(149)		3,597		95,036		11,204
Asset impairment charges		181		808		1,196		2,872
Change in fair value of contingent consideration		(1,030)		3,120		(930)		(787)
Increase in tax receivable agreement liability		11,327		676		26,719		1,907
System implementation expense ⁽³⁾		257		2,016		2,029		4,429
Other		1,581		1,189		(1,913)		3,440
Provision for income taxes ⁽⁴⁾		(15,875)		(15,127)		(48,016)		(42,451)
Net income attributable to non-controlling interests not associated with our Class B common stock		(11,913)		(9,355)		(32,671)		(22,042)
Adjusted net income (Non-GAAP)	$	50,552	$	60,305	$	146,462	$	153,990
Weighted average diluted shares outstanding (Non-GAAP) ⁽⁵⁾		322,946		311,808		319,491		308,402
Adjusted diluted earnings per share (Non-GAAP)	$	0.16	$	0.19	$	0.46	$	0.50

Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited)

Explanations for Reconciliations of Net Income (Loss) to EBITDA and Adjusted EBITDA and Net Income (Loss) to
Adjusted Net Income and Calculation of Adjusted Diluted Earnings per Share

(1)		Acquisition, site closure, and idle facility expenses for the three and nine months ended September 30, 2024 primarily included rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three and nine months ended September 30, 2023 primarily included site closure costs associated with the planned cessation of manufacturing at our Hauppauge, NY facility.
(2)		For the nine months ended September 30, 2024, charges related to legal matters, net were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by political subdivisions and Native American tribes across the United States. For the three months ended September 30, 2023, charges related to legal matters, net were primarily comprised of a charge for the settlement of a customer claim. For the nine months ended September 30, 2023, charges related to legal matters, net were primarily comprised of (i) charges for civil prescription opioid litigation; (ii) settlement of a customer claim; and (iii) settlement of a stockholder derivative lawsuit.
(3)		System implementation expense for the three and nine months ended September 30, 2024 and 2023 was primarily for the implementation of software to further integrate our acquired businesses.
(4)		The non-GAAP effective tax rates for the three and nine months ended September 30, 2024 were 23.9% and 24.7%, respectively. The non-GAAP effective tax rates for the three and nine months ended September 30, 2023 were 20.1% and 21.6%, respectively.
(5)		Weighted average diluted shares outstanding for the three and nine months ended September 30, 2024 consisted of fully diluted Class A common stock. Weighted average diluted shares outstanding for the three and nine months ended September 30, 2023 consisted of diluted Class A common stock and Class B common stock, as if all shares of Class B common stock were converted to Class A common stock as of January 1, 2023.


Amneal Pharmaceuticals, Inc.
Generics Segment
Reconciliation of GAAP to Non-GAAP Operating Results ⁽¹⁾
(unaudited; $ in thousands)

	Three Months Ended September 30, 2024						Three Months Ended September 30, 2023
	As Reported		Adjustments		Non-GAAP		As Reported		Adjustments		Non-GAAP
Net revenue	$	427,345	$	—	$	427,345	$	390,857	$	—	$	390,857
Cost of goods sold ⁽²⁾		249,342		(11,411)		237,931		236,268		(13,437)		222,831
Gross profit		178,003		11,411		189,414		154,589		13,437		168,026
Gross margin %		41.7%				44.3%		39.6%				43.0%

Selling, general and administrative ⁽³⁾		30,951		(1,931)		29,020		33,538		(1,686)		31,852
Research and development ⁽⁴⁾		57,099		(674)		56,425		35,103		(633)		34,470
Intellectual property legal development expenses		1,786		—		1,786		815		—		815
Restructuring and other charges		17		(17)		—		112		(112)		—
(Credit) charges related to legal matters, net		(149)		149		—		(2,500)		(3,000)		(5,500)
Other operating loss		—		—		—		73		—		73
Operating income	$	88,299	$	13,884	$	102,183	$	87,448	$	18,868	$	106,316

(1)		Operating results for the sale of Amneal products by AvKARE were included in our Generics segment.
(2)		Adjustments for the three months ended September 30, 2024 and 2023, respectively, were comprised of stock-based compensation expense ($0.9 million in each period), amortization expense ($10.3 million and $10.5 million), site closure and idle facility expenses (none and $1.1 million), and asset impairment charges ($0.2 million and $0.9 million).
(3)		Adjustments for the three months ended September 30, 2024 and 2023, respectively, were comprised of stock-based compensation expense ($1.4 million and $1.3 million) and site closure costs ($0.5 million and $0.4 million).
(4)		Adjustments for the three months ended September 30, 2024 and 2023 were comprised of stock-based compensation expense.


Amneal Pharmaceuticals, Inc.
Generics Segment
Reconciliation of GAAP to Non-GAAP Operating Results ⁽¹⁾
(unaudited; $ in thousands)

	Nine Months Ended September 30, 2024						Nine Months Ended September 30, 2023
	As Reported		Adjustments		Non-GAAP		As Reported		Adjustments		Non-GAAP
Net revenue	$	1,245,967	$	—	$	1,245,967	$	1,108,364	$	—	$	1,108,364
Cost of goods sold ⁽²⁾		750,167		(35,123)		715,044		692,008		(42,283)		649,725
Gross profit		495,800		35,123		530,923		416,356		42,283		458,639
Gross margin %		39.8%				42.6%		37.6%				41.4%

Selling, general and administrative ⁽³⁾		95,663		(5,251)		90,412		89,178		(5,562)		83,616
Research and development ⁽⁴⁾		123,173		(1,913)		121,260		98,570		(1,901)		96,669
Intellectual property legal development expenses		3,778		—		3,778		3,240		—		3,240
Restructuring and other charges		70		(70)		—		211		(112)		99
Charges (credit) related to legal matters, net ⁽⁵⁾		94,909		(94,909)		—		(2,927)		(7,073)		(10,000)
Other operating income		—		—		—		(1,138)		—		(1,138)
Operating income	$	178,207	$	137,266	$	315,473	$	229,222	$	56,931	$	286,153

(1)		Operating results for the sale of Amneal products by AvKARE were included in our Generics segment.
(2)		Adjustments for the nine months ended September 30, 2024 and 2023, respectively, were comprised of stock-based compensation expense ($2.7 million and $2.9 million), amortization expense ($31.2 million and $32.1 million), site closure and idle facility expenses (none and $4.2 million), asset impairment charges ($1.2 million and $2.9 million), and other (none and $0.2 million).
(3)		Adjustments for the nine months ended September 30, 2024 and 2023, respectively, were comprised of stock-based compensation expense ($3.7 million and $4.0 million) and site closure costs ($1.6 million in each period).
(4)		Adjustments for the nine months ended September 30, 2024 and 2023 were comprised of stock-based compensation expense.
(5)		Adjustment for the nine months ended September 30, 2024 was primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by political subdivisions and Native American tribes across the United States.


Amneal Pharmaceuticals, Inc.
Specialty Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(unaudited; $ in thousands)

	Three Months Ended September 30, 2024						Three Months Ended September 30, 2023
	As Reported		Adjustments		Non-GAAP		As Reported		Adjustments		Non-GAAP
Net revenue	$	115,638	$	—	$	115,638	$	97,304	$	—	$	97,304
Cost of goods sold ⁽¹⁾		52,342		(29,394)		22,948		45,551		(25,844)		19,707
Gross profit		63,296		29,394		92,690		51,753		25,844		77,597
Gross margin %		54.7%				80.2%		53.2%				79.7%

Selling, general and administrative ⁽²⁾		27,723		(167)		27,556		22,756		(235)		22,521
Research and development ⁽²⁾		3,998		(258)		3,740		6,272		(458)		5,814
Intellectual property legal development expenses		181		—		181		71		—		71
Restructuring and other charges		—		—		—		931		(931)		—
Change in fair value of contingent consideration ⁽³⁾		(1,030)		1,030		—		3,120		(3,120)		—
Operating income	$	32,424	$	28,789	$	61,213	$	18,603	$	30,588	$	49,191

(1)		Adjustments for the three months ended September 30, 2024 and 2023 were comprised of amortization expense.
(2)		Adjustments for the three months ended September 30, 2024 and 2023 were comprised of stock-based compensation expense.
(3)		Contingent consideration was recorded in connection with the acquisitions of (i) the baclofen franchise from certain entities affiliated with Saol International Limited and (ii) Kashiv Specialty Pharmaceuticals, LLC.


Amneal Pharmaceuticals, Inc.
Specialty Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(unaudited; $ in thousands)

	Nine Months Ended September 30, 2024						Nine Months Ended September 30, 2023
	As Reported		Adjustments		Non-GAAP		As Reported		Adjustments		Non-GAAP
Net revenue	$	324,913	$	—	$	324,913	$	285,976	$	—	$	285,976
Cost of goods sold ⁽¹⁾		143,284		(81,349)		61,935		135,254		(77,871)		57,383
Gross profit		181,629		81,349		262,978		150,722		77,871		228,593
Gross margin %		55.9%				80.9%		52.7%				79.9%

Selling, general and administrative ⁽²⁾		79,529		(755)		78,774		67,894		(649)		67,245
Research and development ⁽²⁾		13,276		(801)		12,475		19,294		(1,334)		17,960
Intellectual property legal development expenses		215		—		215		110		—		110
Restructuring and other charges		1,024		(1,024)		—		1,013		(1,013)		—
Change in fair value of contingent consideration ⁽³⁾		(930)		930		—		(787)		787		—
Operating income	$	88,515	$	82,999	$	171,514	$	63,198	$	80,080	$	143,278

(1)		Adjustments for the nine months ended September 30, 2024 and 2023 were comprised of amortization expense.
(2)		Adjustments for the nine months ended September 30, 2024 and 2023 were comprised of stock-based compensation expense.
(3)		Contingent consideration was recorded in connection with the acquisitions of (i) the baclofen franchise from certain entities affiliated with Saol International Limited and (ii) Kashiv Specialty Pharmaceuticals, LLC.


Amneal Pharmaceuticals, Inc.
AvKARE Segment
Reconciliation of GAAP to Non-GAAP Operating Results ⁽¹⁾
(unaudited; $ in thousands)

	Three Months Ended September 30, 2024						Three Months Ended September 30, 2023
	As Reported		Adjustments		Non-GAAP		As Reported		Adjustments		Non-GAAP
Net revenue	$	159,485	$	—	$	159,485	$	131,879	$	—	$	131,879
Cost of goods sold		131,226		—		131,226		105,690		—		105,690
Gross profit		28,259		—		28,259		26,189		—		26,189
Gross margin %		17.7%				17.7%		19.9%				19.9%

Selling, general and administrative ⁽²⁾		15,145		(3,545)		11,600		14,313		(3,657)		10,656
Operating income	$	13,114	$	3,545	$	16,659	$	11,876	$	3,657	$	15,533

(1)		Operating results for the sale of Amneal products by AvKARE were included in our Generics segment.
(2)		Adjustments for the three months ended September 30, 2024 and 2023 were comprised of amortization expense ($3.5 million and $4.2 million) and other (none and ($0.5) million).


Amneal Pharmaceuticals, Inc.
AvKARE Segment
Reconciliation of GAAP to Non-GAAP Operating Results ⁽¹⁾
(unaudited; $ in thousands)

	Nine Months Ended September 30, 2024						Nine Months Ended September 30, 2023
	As Reported		Adjustments		Non-GAAP		As Reported		Adjustments		Non-GAAP
Net revenue	$	492,559	$	—	$	492,559	$	382,286	$	—	$	382,286
Cost of goods sold		412,423		—		412,423		318,626		—		318,626
Gross profit		80,136		—		80,136		63,660		—		63,660
Gross margin %		16.3%				16.3%		16.7%				16.7%

Selling, general and administrative ⁽²⁾		44,694		(10,636)		34,058		41,268		(11,609)		29,659
Operating income	$	35,442	$	10,636	$	46,078	$	22,392	$	11,609	$	34,001

(1)		Operating results for the sale of Amneal products by AvKARE were included in our Generics segment.
(2)		Adjustments for the nine months ended September 30, 2024 and 2023, respectively, were comprised of amortization expense ($10.6 million and $12.6 million) and other (none and ($1.0) million).

View source version on businesswire.com: https://www.businesswire.com/news/home/20241108530772/en/

Contact

Anthony DiMeo

VP, Investor Relations

anthony.dimeo@amneal.com

Source: Amneal Pharmaceuticals, Inc.

FAQ

What was Amneal's (AMRX) revenue in Q3 2024?

Amneal reported net revenue of $702 million in Q3 2024, representing a 13% increase from $620 million in Q3 2023.

Did Amneal (AMRX) make a profit in Q3 2024?

No, Amneal reported a net loss of $0.2 million in Q3 2024, compared to a net income of $10 million in Q3 2023.

What is Amneal's (AMRX) revenue guidance for 2024?

Amneal affirmed its 2024 full-year guidance with projected net revenue of $2.70-2.80 billion.

What new products did Amneal (AMRX) launch in Q3 2024?

Amneal launched CREXONT® for the treatment of Parkinson's disease in Q3 2024.

Amneal Reports Third Quarter 2024 Financial Results

Insights

FAQ

What was Amneal's (AMRX) revenue in Q3 2024?

Did Amneal (AMRX) make a profit in Q3 2024?

What is Amneal's (AMRX) revenue guidance for 2024?

What new products did Amneal (AMRX) launch in Q3 2024?

NASDAQ:AMRX

AMRX Rankings

AMRX Latest News

AMRX Stock Data

Trending News

Amneal Reports Third Quarter 2024 Financial Results

Insights

Financial Analyst neutral

Medical Research Analyst positive

FAQ

What was Amneal's (AMRX) revenue in Q3 2024?

Did Amneal (AMRX) make a profit in Q3 2024?

What is Amneal's (AMRX) revenue guidance for 2024?

What new products did Amneal (AMRX) launch in Q3 2024?

NASDAQ:AMRX

AMRX Rankings

AMRX Latest News

AMRX Stock Data